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A B S T R A C T
Background and Objective: The goal was to measure Health Related Quality of Life (HRQoL) in individuals with
different types of dementia, mild cognitive impairment (MCI) and healthy controls (HC), and assess agreement
levels between participants and proxies.
Materials and Methods: A sample of 136 participants were recruited; thirty-seven with Alzheimer’s Disease
Dementia (AD), 19 with Dementia with Lewy Bodies (DLB), 12 with Frontotemporal Dementia (FTD), 37 with
MCI and 31 HC. HRQoL was measured via the 12-Item Short Form Health Survey, version 2 (SF-12-v2), sepa-
rately for participants and proxies. Two groups (Individuals with cognitive decline versus healthy controls) were
matched for sociodemographic variables. Differences for discrepancy rates between both groups were measured
using t-test. Participant and proxy agreements were measured via Intraclass Correlation Coefficients (ICC).
Linear regression analyses were performed to examine what variables explained better the variance observed.
Results: Patients with DLB and FTD showed the lowest levels of HRQoL, while AD and HC showed the highest.
No statistically significant differences were found between discrepancy scores from cognitive decline groups and
healthy controls. ICC indicated high agreement between patients and proxies for the groups with cognitive
decline, while agreements achieved in HC were lower and only in physical indices. GDS score accounted for
8.3% of the variance of proxies’ rating on Mental Summary Composite Score (MSC).
Conclusion: HRQoL physical and mental summaries are more reliable in groups with cognitive decline. Healthy
controls and their proxies show lower agreement, with proxies reporting lower levels than normal for some
relevant indices.
1. Introduction
In the latest 10–15 years, dementia has been a target condition for
studies that have developed treatments to improve cognitive status,
delay severe symptoms onset, maximize daily life functioning of pa-
tients and reduce behavioural disorders. However, despite the wide
variety of approaches for dementia patients, the outcomes only show
moderate rates of success (Logsdon, Gibbins, McCurry, & Teri, 2002).
Moreover, new challenges and targets have raised not only in relation
to the patients with dementia themselves, but also to their environment
(Gwyther, 1997). Variables such as Health Related Quality of Life
(HRQoL) are essential for a comprehensive approach of the disease, and
very useful to inform about disease progression, such as cost-effec-
tiveness models on dementia. Indeed, it is recognized as a high valued
health outcome measure in dementias (Landeiro, Walsh, & Ghinai,
2018).
World Health Organization defines HRQoL as the personal percep-
tion with regards to one’s own vital position in relation to his/her
achievements, expectations, standards and concerns (Sartorius, 1990s).
There are three levels of HRQoL measurement: (1) by means of disorder
specific instruments, (2) finding generic health profiles, and (3) by
means of studies using a cost-utility analysis (Wlodarzcyk, Brodaty, &
Hawthorne, 2004). Up to date, most studies on this area have focused
their efforts in the conceptual analysis of HRQoL in dementia, as well as
in the study of psychometric properties of selected developed instru-
ments, thus showing evidence of the relationship between HRQoL and
clinical variables such as cognition, limitations in Daily Life Activities,
behavioural disorders, depression or caregiver burden (Banerjee, Samsi,
& Petrie, 2009). Subsequently, and due to the wide extension of
symptoms associated to dementia, there is an increasing consensus on
the need to measure variables and constructs such as HRQoL, that need
to be measured and given similar relevance to those related to cognition
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and behaviour (Rabins & Black, 2007; Whitehouse, 2000). The implicit
difficulty to measure this variable lies on its dependency on the pa-
tient’s communication skills to express their impressions to the eva-
luator, as well as on the tendency to be compliant with the evaluator
(Wlodarzcyk et al., 2004). Measurements of HRQoL are useful not only
when it comes to analyse the impact of the disease on patients, but also
when there is a need to objectivize the effects of intervention, according
to Schwartz (2013). This same author emphasizes the usefulness of this
type of measurements, not only for the design of services and resources
for people with cognitive decline who enter a nursing home, but also for
the establishment of priorities and treatment requirements.
The Mini Mental State Examination (MMSE) score does not correlate
with HRQoL self-perception, or with caregivers’ reports (Logsdon et al.,
2002; Vogel, Mortensen, Hasselbalch, Andersen, & Waldemar, 2006).
Age and behavioural disorders, on the contrary, substantially influence
HRQoL rates reported by caregivers in dementia (Banerjee, Smith, &
Lamping, 2006, 2009), while these variables do not seem to affect pa-
tients’ ratings. This raises the need to evaluate the differential impact
that dementia may have on patients and caregivers, and to consider
how the decline of awareness in dementia may affect the outcomes
(Banerjee et al., 2006; Logsdon et al., 2002). Other variables affecting
HRQoL are: (1) gender (Woods, Thorgrimsen, Spector, Royan, & Orrell,
2006); (2) depressive disorders (Logsdon et al., 2002), (3) anxiety
disorders (Banerjee et al., 2006), whose treatment considerable im-
proves HRQoL rates (Woods et al., 2006) and (4) functional status
(Karlawish, Lu, Logsdon, Whitehouse, & Aisen, 2004).
In a longitudinal study with 47 patients with dementia, only a lower
baseline score in an Alzheimer specific quality of life scale was asso-
ciated with greater decline in the follow‐up, with no associations be-
tween sociodemographic variables, baseline ratings of dementia se-
verity (MMSE), impairment in activities of Daily Living (ADL),
behavioural impairment, depression, or MMSE change during follow‐up
(Lyketsos et al., 2003). When early interventions take place, low
baseline scores can improve dramatically (Banerjee et al., 2007;
Zimmerman, Sloane, & Williams, 2005). By implementing a cognitive
stimulation therapy on a group basis, studies report improvements
when compared to control groups (Spector, Thorgrimsen, & Woods,
2003), though their maintenance does not last for long and HRQoL
scores decrease together with MMSE scores (Orrell, Spector,
Thorgrimsen, & Woods, 2005). Female patients seem to benefit more
from intervention, while male patients lacking any treatment perform
worse (Woods et al., 2006).
When comparing quality of life among chronic diseases, HRQoL in
individuals with dementia could appear relatively preserved.
Nevertheless, when sociodemographic variables are taken into account,
patients with dementia experience the largest decline. Moreover,
quality of life declines with advanced age, while dementias develop
more frequently in late ages (Esteban y Peña, Hernández, & Fernández,
2010). The type of dementia also affects HRQoL scores, with worse
ratings for Dementia with Lewy Bodies (DLB) (Banerjee et al., 2009).
The main methodological challenge relies on the subjectiveness of
HRQoL measures, especially when self-reporting may be especially
compromised in conditions affecting insight abilities, emotional and
affective skills, and in which a tendency to distort reality may take
place (Wlodarzcyk et al., 2004). Many studies have pointed out the
need to collect informants’ views, although other studies state that
these views may be biased and that patients’ own views and reports
should be prioritized (Herrman, Hawthorne, & Thomas, 2002).
While some studies suggest that HRQoL measurements are only
possible with mild to moderate dementia, it seems that proxies, both
formal and informal caregivers, share a different opinion. Consistent
associations were found between proxies’ report and cognitive decline,
decrease in activity participation, depression and agitation (Sloane
et al., 2005), while no associations were found based on patients’ self-
reports. Some features of the proxies (overburden, depression, educa-
tional level and support from professional caregivers) influence their
view on patients’ HRQoL, being their ratings significantly worse than
those of patients’ themselves (Vogel et al., 2006). Although frequently it
is stated that this may be due to dementia patients’ low comprehension
skills and caregivers’ high level of criticism, Evans and Huxley (2005)
state that this is because dementia implies a process of adaptation to a
disability in which people with dementia mark and adjust expectations
and responses to changes. In fact, this discrepancy was not only re-
ported for dementia.
Albrecht and Devilieger (Albrecht & Devlieger, 1999) already
coined the term ‘disability paradox’ to refer to the fact that half of the
people with disabilities report a good or even excellent quality of life. In
the case of caregivers of individuals with dementia, chronicity and long
development of the disease, linked to a bad prognosis, prevent this
paradox to take place and, instead, increase significantly caregivers’
stress levels (Clipp & George, 1993). A way to minimize the impact of
their own stress when responding to HRQoL questionnaires is to in-
struct the proxy to answer as if they were the person with dementia
(Karlawish, Casarett, Klocinski, & Clark, 2001). Both perspectives seem
to conform complementary approaches to HRQoL (Banerjee et al.,
2009).
Latest studies show that data for dementia specific HRQoL measures
can be obtained using subjective reports from patients and proxies
(Logsdon et al., 2002). Measures are quick and easy to use, and have
been tested in a variety of cases and situations (Banerjee et al., 2009).
The National Institute for Health and Clinical Excellence states and proves
an improvement of HRQoL measures and their usefulness for inter-
vention in dementia cases (National Institute for Health & Care
Excellence, 2006; Winblad, Brodaty, & Gauthier, 2001). In this sense, it
is of great relevance to redefine what constitutes treatment success in
order to incorporate patient’s lifestyle variables.
With this idea of the relevance of HRQoL for dementia treatment
planning, the goal of the current study was to measure self-reported
Health Related Quality of Life (HRQoL) in individuals with different
types of dementia, mild cognitive impairment (MCI) and healthy con-
trols (HC), as well as those reports delivered by their proxies (relatives,
caregivers…), and to assess agreement levels between participants and
their proxies. We hypothesized, based on previous research, the ex-
istence of high levels of discrepancy between participants and proxies
across all HRQoL domains.
2. Method
The study comprised an incidental sample of 136 participants di-
vided in 5 groups: (a) 37 individuals with a diagnosis of Alzheimer’s
Dementia (AD); (b) 19 individuals with a diagnosis of Dementia with
Lewy Bodies –DLB-; (c) 12 individuals with Frontotemporal
Dementia–FTD- and (d) 37 individuals with a diagnosis of Mild
Cognitive Impairment –MCI-. Moreover, a control group was available:
(e) 31 individuals with no cognitive decline, namely Healthy Controls
−HC-, recruited from older adults’ associations in the same geo-
graphical area, and that were matched with the rest of the groups based
on age, gender, years of education and family history of primary de-
generative dementias (thus, HC did not differ significantly from clinical
groups in any of the grouping variables). People who attended a neu-
rology clinic and fulfilled the inclusion criteria were invited to vo-
luntarily participate in NeuroDemeNPSia study, in which cross-sec-
tional measures of psychological and neuropsychological variables
were taken. Inclusion criteria included:
(1) cognitive decline due to a degenerative primary dementia (AD, DLB
or FTD) (with scores in the GDS scale of 3 or 4) (Reisberg, Ferris, de
Leon, & Crook, 1982), or due to a mild cognitive impairment but
not dementia (MCI). Those scoring 1 or 2 in the Global Deteriora-
tion Scale (GDS) and showing a regular cognitive performance
(meaning that they are not above –i.e. super agers that may con-
stitute as outliers - or below two standard deviations from the mean
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–i.e. individuals with MCI or dementia - in the administered cog-
nitive tests) were included as HC;
(2) individuals with a diagnosis of AD had to fulfil National Institute of
Neurological and Communicative Disorders and Stroke and the
Alzheimer's Disease and Related Disorders Association (NINCDS-
ADRDA) diagnostic criteria (Dubois, Feldman, & Jacova, 2007);
those with DLB had to fulfil DLB International Workshop diagnostic
criteria (McKeith, Dickson, & Lowe, 2005); those with FTD had to
fulfil the criteria from the Work Group Frontotemporal Dementia
and Pick’s Disease (McKhann et al., 2001). Individuals with MCI
had a score of 3 in the GDS and fulfil criteria from the Spanish
Neurological Society (SEN) (Robles, Del Ser, Alom, Peña Casanova,
& grupo asesor del GNCD de la SEN, 2002), which imply (a) an
impairment in one or more cognitive areas –attention/concentra-
tion, language, gnosias, memory, praxias, visuospatial and execu-
tive functions-; (b) this impairment has to be acquired, reported by
the patient or a reliable proxy, objectivized via neuropsychological
assessment, lasting for several months, and evidenced in the patient
with a normal level of consciousness; (c) the cognitive impairment
only interferes minimally with instrumental or advanced activities
of daily living, and (d) the cognitive impairment is not associated
with disorders on the level of consciousness;
(3) all received a diagnosis by a neurologist from a primary care setting
in the Greater Bilbao area (Spain);
(4) all signed a consent form, with explicit authorization to participate
given by the individual and, where required, from their caregiver.
Exclusion criteria followed in this study included: (1) suffering from
conditions associated to decline in intellectual functions, such as cere-
bral infections, stroke, encephalic degenerative diseases, psychiatric
disorders, or showing conditions affecting functionality and prevent
their participation in the study (deafness, blindness…), all of it con-
firmed by the clinical record and a check-up by a neurologist; more
specifically, those patients with any type of vascular factor were dis-
carded in order to properly adjust to Primary Degenerative Dementia
aetiology. It was specifically confirmed, patient by patient, by means of
an fMRI no older than 6 months, that no individual had any issue
suggesting vascular aetiology, but instead that fMRI results matched
‘expected’ results -i.e. fMRI within expected parameters of absence of
vascular components; (2) those with problems to read or understand the
contents of the administered questionnaires, and (3) those lacking a
companion or informal caregiver that may respond as the main care-
giver were also excluded. With regards to this, the main inclusion cri-
teria for proxies was that they had known or met the participant fre-
quently (on a daily or close to daily basis) for at least 6 months prior to
the assessment. The study fulfilled all the ethical requirements and
obtained the required ethical approval from the University of [blinded
for review]
HRQoL was measured by means of the SF-12(v.2) questionnaire,
developed by Ware, Kosinski, Turner-Bowker and Gandek (2005) and
that includes 8 factors or subscales (Physical Function, Physical Role,
Body Pain, General Health, Vitality, Social Function, Emotional Role
and Mental Health) and 2 summary composite measures (physical–PSC-
and mental –MSC-). Scoring ranges from 0 to 100, where higher scores
mean a better health-related quality of life. Research on this scale has
shown internal consistency scores higher than 0.70 and significant
correlations between the different versions of the scale (Jenkinson &
Layte, 1997), and a recent study with AD patients has shown alpha
levels for different subscales ranging from 0.69 to 0.88 (Cole et al.,
2014). The questionnaires were self-reported but the evaluator was
present to clarify any doubts they might have, and if this was not en-
ough, as reported above, those with reading or comprehension pro-
blems were excluded.
Norms and weights from the American version were used in absence
of a full validation of the scale with Spanish population. Estimation of
dimensions and summary composite scores was performed by means of
the standard method that uses an algorithm with the mean scores,
standard deviations and factorial weights in general population (Ware
et al., 2005), leading to comparable typified scores. Thus, the algorithm
generates, for each domain, a new variable with a mean of 50 (Standard
Deviation of 10), which corresponds with the American norms mean
through a linear transformation of punctuations, as other authors do
with this instrument (Monteagudo, Hernando, & Palomar, 2011). This
way, the direct interpretation of results is easier (i.e. the higher the
score, the better the HRQoL).
Data were analyzed using the Statistical Package for Social Sciences
(SPSS), version 23.0 for Windows. The p-value was set in .05. We
compared HRQoL self-reports of patients with dementia with reports
given by their main caregivers (proxies). To do that, we performed
IntraClass Correlation (ICC) analyses, as well as t-test analyses to
compare the clinical groups and control group. As defined by Shrout
and Fleiss (1979), the ICC is the correlation between one measurement
(either a single rating or a mean of several ratings) on a target and
another measurement obtained on that target. In our case, a correlation
between participants’ and proxies’ report was calculated. Moreover,
linear regression analyses were performed in order to see what vari-
ables explained better the variance observed in the results (both for
participants and proxies). More specifically, participants’ age, GDS
score and years of formal education were used as predictors, separately
for proxies’ and participants’ ratings. Clinical groups were matched by
sociodemographic variables, in order to control the effects of gender
(one-tailed p-values) (χ2= 4.005; p= .405), age (χ2= 1.961;
p= .161), years of formal education (χ2= 4.947; p= .084) and family
history of dementia (mother, χ2= 3.112; p= .539; father, χ2= 6.009;
p= .198; siblings, χ2= 0.911; p= .923; paternal uncles, χ2= 3.881;
p= .422; maternal uncles, χ2= 1.330; p= .856; paternal grand-
parents, χ2= 2.549; p= .636; maternal grandparents, χ2= 3.487;
p= .480; partner, χ2= 5.367; p= .252; maternal cousin, χ2= 2.896;
p= .575 and paternal cousin, χ2= 4.970; p= .290).
3. Results
Table 1 shows the sociodemographic variables and MMSE scores for
all the participant subgroups. All groups had a mean age of around
75–76 years (with the exception of the MCI group, which, as would be
expected, was younger). Individuals with AD showed fewer years of
education than the rest of the groups. Regarding the general cognitive
state measured by the MMSE, while the groups with dementia were
below the cut point considered as cognitive impairment (< 24 points,
generally), the MCI group was in the range of suspicion for possible
cognitive impairment (24–27 points) and healthy controls were above
that range.
Table 1
Sociodemographic variables and MMSE scores.
Variables AD (n=37) LBD (n= 19) FTD (n=12) MCI (n= 37) HC (n= 31)
Sex Male N (%) 17 (46%) 10 (52.63%) 6 (50%) 12 (32.43%) 9 (29%)
Female N (%) 20 (54%) 9 (47.37%) 6 (50%) 25 (67.57%) 22 (71%)
Age - (mean± SD) 76.66 ± 6.59 77.95 ± 7.71 75.77 ± 6.21 70.89 ± 11.05 74.68 ± 6.35
Years of education (mean± SD) 6.46 ± 3.40 7.44 ± 2.68 7.58 ± 3.42 9.64 ± 5.53 8.36 ± 3.40
MMSE score (mean± SD) 20.39 ± 3.80 21.63 ± 3.99 22.00 ± 3.74 25.41 ± 3.18 28.11 ± 1.32
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Regression analyses showed that, for proxies, GDS score (ß=
-0.269; p= .001) accounted for 8.3% of the variance of proxies’ rating
on Mental Summary Composite Score (MSC) (R=0.321, corrected
R2=0.083), while age (ß= 0.019; p= .058) and years of education
(ß= -0.02; p= .928) could not be considered significant predictors.
However, this model could not explain proxies’ rating on Physical
Summary Composite Score (PSC). Separately, this same regression
model was not significant for the prediction of scores reported by
participants’ themselves.
Table 2 shows the results for the 12-Item Short Form Health Survey,
version 2 (SF-12-v2). Both patient’s and an informant’s (i.e. relative or
main caregiver) questionnaires were collected. In this case, the in-
formants needed to answer to the questions as if they were the patients
themselves. It is remarkable, among other measures, the low levels for
Physical Role, Social Function and Emotional Role for healthy controls
as reported by their proxies. As it can be seen, patients with DLB and
FTD showed the lowest levels of HRQoL, while AD and HC showed the
highest. These differences between groups have extensively been re-
ported and discussed elsewhere (Onandia-Hinchado & Diaz-Orueta,
2019).
In order to observe to what extent respondents agreed with their
proxies (comparing separately cognitive decline - four dementia groups
plus MCI- versus HC), Intraclass Correlation Coefficients were calcu-
lated to measure the level of respondent-proxy agreement, as shown in
Table 3.
As it can be seen, there were many moderate to high ICC (Fleiss,
2011), especially in the groups with cognitive decline, who had a larger
number of factors with agreement between patients and proxies, and of
higher intensity than in healthy controls. As it can be seen in the group
with cognitive decline, those agreements were higher in those compo-
nents that are more tangible and visible (i.e. Physical Function, Physical
Role, Body Pain, and, subsequently, in the PSC score) than in ‘mental’
indices. The few agreements achieved by HC group were also seen in
physical indices.
Finally, knowing the agreement levels between the participants’ and
their proxies (separately for participants with cognitive decline and
healthy controls), Table 4 compares the mean differences of dis-
crepancy scores obtained between the groups with cognitive decline
and healthy controls. As we can observe, no statistically significant
differences were found between discrepancy scores of the cognitive
decline groups (i.e. four dementia groups plus MCI) and HC.
4. Discussion
The goal of the current study was to measure self-reported Health
Related Quality of Life in individuals with different types of dementia,
mild cognitive impairment (MCI) and healthy controls (HC), as well as
their proxies, and to assess participant-proxy agreement levels. We
hypothesized, based on previous research, that discrepancies between
participants and proxies across all HRQoL domains would be high and
significant. However, in terms of patient-caregiver agreement, the le-
vels of agreement are strong in the groups with cognitive decline (de-
mentia groups plus MCI patients), which suggests that patient centred
measures are reliable and are coincidental to those reported by their
own caregivers, who are the ones who best know them. It is possible
that early signs and symptoms of dementia in earlier stages make both
patients and proxies adjust their expectations and rate decline in later
stages in a more realistic way, but that assumption would require fur-
ther research. This seems to contradict other authors’ statements
(Banerjee et al., 2006, 2009; Logsdon et al., 2002) in relation to loss of
insight and its influence in HRQoL self-assessment (or, at least, it may
not apply to mild to moderate stages of decline). However, in order for
this reliability to be stronger, the type of variables that are more con-
veniently self-reported are preferably those related to physical func-
tioning. In any case, this study supports previous studies stating the
need to complement HRQoL assessment with both patients and proxies’
reports (Banerjee et al., 2009).
We also observed that, attending to the percentage of variance
Table 2
HRQoL features of the sample.
HRQoL Variables (Percentage ± SD) AD (n= 37) DLB (n=19) FTD (n= 12) MCI (n= 37) HC (n= 31)
Physical Function (patient) 83.97 ± 30.61 63.04 ± 34.44 69.64 ± 41.81 75 ± 35.36 80.65 ± 27.16
Physical Function (proxy) 82.24 ± 28.42 52.38 ± 32.50 59.62 ± 41.51 68.92 ± 36.52 76.79 ± 28.81
Physical Role (patient) 82.43 ± 34.42 52.98 ± 43.28 69.64 ± 38.20 69.23 ± 36.93 83.62 ± 23.88
Physical Role (proxy) 61.84 ± 28.47 35.71 ± 31.20 33.65 ± 32.43 52.70 ± 29.04 63.39 ± 21.50
Body Pain (patient) 90.38 ± 24.07 78.26 ± 32.25 82.14 ± 31.67 80.49 ± 34.69 80.65 ± 33.98
Body Pain (proxy) 84.21 ± 28.72 77.38 ± 35.27 80.77 ± 37.02 75 ± 32.81 85.71 ± 19.75
General Health (patient) 49.10 ± 22.50 37.17 ± 27.71 35.71 ± 19.89 50 ± 25.12 56.61 ± 21.46
General Health (proxy) 51.71 ± 23.49 39.29 ± 24.71 35.77 ± 32.14 48.24 ± 26.41 62.32 ± 25.15
Vitality (patient) 75 ± 30.89 64.77 ± 37.53 76.79 ± 31.72 54.89 ± 38.41 76.61 ± 28.82
Vitality (proxy) 75 ± 27.26 73.81 ± 26.78 57.69 ± 29.55 74.32 ± 27.94 92.86 ± 19.07
Social Function (patient) 93.57 ± 19.50 81.82 ± 32.90 87.50 ± 23.51 81.41 ± 16.15 90.18 ± 26.65
Social Function (proxy) 65.13 ± 22.16 53.57 ± 35.61 55.77 ± 32.52 50.68 ± 33.04 65.18 ± 21.88
Emotional Role (patient) 92.23 ± 16.76 65.48 ± 41.44 80.35 ± 31.28 81.09 ± 31.13 87.50 ± 16.41
Emotional Role (proxy) 57.24 ± 28.86 47.62 ± 30.78 56.73 ± 30.45 55.07 ± 28.63 69.20 ± 14.22
Mental Health (patient) 75.66 ± 22.69 68.18 ± 24.92 66.07 ± 26.14 69.82 ± 28.23 77.02 ± 21.19
Mental Health (proxy) 66.12 ± 16.92 61.90 ± 19.56 60.58 ± 18.29 61.82 ± 19.53 76.34 ± 13.75
Physical summary (patient) 49.13 ± 11.57 40.48 ± 13.34 44.23 ± 13.14 45.33 ± 11.95 48.10 ± 11.23
Physical summary (proxy) 49.08 ± 10.59 41.57 ± 9.20 40.44 ± 13.92 45.08 ± 10.09 47.90 ± 8.90
Mental summary (patient) 55.15 ± 9.10 50.65 ± 11.41 51.90 ± 11.26 50.12 ± 12.36 55.05 ± 8.86
Mental summary (proxy) 44 ± 9.98 42.35 ± 11.18 43.24 ± 9.12 42.78 ± 10.55 50.67 ± 6.22
Table 3
Agreement between patients and proxies (ICC).
HRQoL Indices and
Composite Scores
Cognitive Decline Groups (MCI




Physical Function .877* .646*
Physical Role .703* .812*
Body Pain .810* .652*
General Health .633* .605*
Vitality .583* .053
Social Function .759* −.309
Emotional Role .570* .476







*p= .01; **p= .05 (p-value: 2-tailed).
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explained by cognitive decline (i.e. GDS) in caregivers’ opinions, their
ratings of patients’ HRQoL seem to be only slightly influenced by this
variable. Thus, although according to other authors’ findings (Banerjee
et al., 2006), age seems to have a great impact on HRQoL ratings with
dementia populations (so that it could condition differences in ratings
between patients and caregivers), we do not find this age related bias in
our study.
Separately, the agreement between healthy controls and their
proxies are weaker, with relatives reporting significantly lower rates.
There are no conclusive explanations for these results, however, they
may suggest a potential underdiagnosis of many pathologies affecting
cognitive status and, especially, awareness or insight. In other words, it
is plausible that some individuals in the HC sample (as it may happen in
general population) can mask their symptomatology and try to over-
compensate their deficits, which may place them under the effect of the
‘disability paradox’ (Albrecht & Devlieger, 1999).
Limitations of this study are clear. Our small sample size may have
not reflected the age bias shown in previous studies when it comes to
rate HRQoL by proxies. In addition, reasons for discrepancies between
healthy controls and proxies are only tentative, and require further
analysis and research. For the proxies, the criteria of a familiarity re-
lationship between the participant and their proxy of at least 6 months
was followed (as required by the administered questionnaire), but the
small sample size did not allow to differentiate between formal and
informal caregivers, which would be interesting but beyond the scope
of the current study. In terms of the HRQoL questionnaire used, at the
time of data collection there were no normative data for the Spanish
population, which explains why the American version translated to
Spanish was used instead, thus leading to a more cautious interpreta-
tion of obtained data. A further consideration of the reasons for
agreement in HRQoL between patients and proxies would have bene-
fited from comparisons between patients and proxies at each dementia
subgroup level, which was not possible in our study due to the small
sample size in some subgroups. However, the specific differences be-
tween dementia subtypes in HRQoL ratings between patients and
proxies would merit further research and could provide additional va-
luable information to discuss the usefulness of HRQoL rates as an ad-
ditional resource to differentiate between dementia subtypes. Further
studies with larger, more representative samples and with dedicated,
norm-based measures for HRQoL are required, but this study opens the
door to a significant further consideration of HRQoL in populations
with cognitive decline, also when developing intervention programmes
that focus both on cognitive and functional outcomes.
Altogether, findings of the current study represent a reaffirmation of
the usefulness of HRQoL measures and the need to take them into ac-
count in clinical assessment settings, as well as in intervention contexts.
Likewise, the need to take into account both patients’ and proxies’
perceptions about HRQoL is evident (Schwartz, 2013). In this way, it
has recently been shown how the dementia course and progress is af-
fected by variables other than those of classical cognitive nature. Thus,
Martyr et al (Martyr et al., 2018) have recently reported about the
complexity of quality of life in dementia and the need to go beyond
cognitive variables; more specifically, to include levels of behavioural
and psychological disturbance (agitation, depression, anxiety, disin-
hibition, and irritability, among others) when accounting for the impact
of quality of life in dementia. Findings of the current study may be of
high relevance when planning for interventions that are com-
plementary to pharmacological and cognitive rehabilitation. These
envisioned interventions should target, not only the control of anxiety
and depression comorbidities, but also the adaptation of patients to
their disorders, adjustment of expectations, perception of functionality
at all levels, and the aim to cover all basic needs. Moreover, interven-
tions targeting disease awareness would imply a significant gain that
would allow to preserve the ability to estimate one’s own HRQoL for
longer periods. Finally, measures of HRQoL could assist in monitoring
the progress and efficacy of different treatments, supporting a higher
personalization of interventions.
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